Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis

Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis

Multiple Myeloma (MM) is a malignant disorder of plasma cells which, despite significant advances in treatment, remains incurable. Daratumumab, the first CD38 directed monoclonal antibody, has shown promising activity alone and in combination with other agents for MM treatment. Daratumumab is though...

Full description

Bibliographic Details
Main Authors: Serika D Naicker, Claire L Feerick, Kevin Lynch, Dawn Swan, Cian McEllistrim, Robert Henderson, Niamh A Leonard, Oliver Treacy, Alessandro Natoni, Athina Rigalou, Joana Cabral, Christopher Chiu, Kate Sasser, Thomas Ritter, Michael O’Dwyer, Aideen E Ryan
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:OncoImmunology
Subjects:
multiple myeloma
daratumumab
cyclophosphamide
macrophages
adcp
Online Access:http://dx.doi.org/10.1080/2162402X.2020.1859263

Internet

http://dx.doi.org/10.1080/2162402X.2020.1859263

Similar Items